Advertisement
Document › Details
BioGenCell Ltd.. (5/9/22). "Press Release: BioGenCell Raises $16 Million Seed Round Led by Marius Nacht for Microvascular Diseases Treatement".
The Israeli startup uses stem cells from the patient’s own blood to treat microvascular diseases and is aiming to develop products that may be usable to restore tissues damaged by diabetes, kidney failure, pulmonary hypertension, heart failure, stroke, blindness, and more
BioGenCell has completed a $16 million Seed round led by private investor Marius Nacht. BioGenCell, which was founded by Dr. Yael Porat and Prof. Michael Belkin, develops technology for using stem cells from the patient’s own blood to treat microvascular diseases.
Read more obout it in the following links:
"BioGenCell raises $16m. for chronic disease treatment."
Read from Jerusalem Post here
https://www.jpost.com/business-and-innovation/tech-and-start-ups/article-706214
"BioGenCell raises $16 million Seed round led by Marius Nacht for microvascular diseases treatment."
Read from Calcalist here
https://www.calcalistech.com/ctechnews/article/sywu8eil5
"BioGenCell completes $16 million seed round, gears for Phase 2 trial."
Read from Israel Hayom here
https://www.israelhayom.com/2022/05/10/biogencell-completes-16-million-seed-round-gears-for-phase-2-trial/
Record changed: 2024-08-24 |
Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top